Controlling Zoonotic Viral Diseases from One Health Perspective 2025

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Animal Viruses".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 4696

Special Issue Editors


E-Mail Website
Guest Editor
Emerging Pathogens Institute, University of Florida, Gainesville, FL 32608, USA
Interests: infectious diseases; arboviruses; encephalitis; SARS-CoV-2; one health
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Montana Veterinary Diagnostic Laboratory, Montana State Department of Livestock, 1911 W. Lincoln Street, Bozeman, MT 59718, USA
Interests: one health; microbiology; infectious diseases; virology; arboviruses; zoonoses; diagnostics

Special Issue Information

Dear Colleagues,

Zoonotic diseases represent the largest proportion of newly emerging and re-emerging infectious diseases. Viral zoonoses include those that jump directly and indirectly between animals and humans. Viral zoonotic transmission occurs at points of contact between humans and both wild and domesticated animals, with the risks of spillover events influenced by host and environmental factors. The prevention, response, and mitigation of zoonotic disease transmission is multifactorial, and the development of an integrated One Health approach for managing and preventing transmission is essential to prevent the next pandemic.

This Special Issue will cover recent developments in viral zoonoses with a focus on One Health strategies for the containment and mitigation of viral zoonotics. We welcome the submission of research articles, review articles, and short communications relevant to this Special Issue. We invite studies on aspects of control including, but not limited to, novel therapeutic development, vaccine strategies, and methods for environmental control. Epidemiology and methods for surveillance with an emphasis on building predictive models and preventative strategies are also welcome.

Dr. Maureen T. Long
Dr. Erika Schwarz-Collins
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • one health
  • viral zoonoses
  • control
  • vaccine
  • surveillance
  • epidemiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2569 KiB  
Article
Development of Quantitative Real-Time PCR and Loop-Mediated Isothermal Amplification Assays for the Surveillance and Diagnosis of Herpes B Virus Infection
by Murasaki Amano, Krittiga Sapkanarak, Wipaporn Thbthimthong, Suthirote Meesawat, Taratorn Kemthong, Nutchanat Suttisan, Haruka Abe, Suchinda Malaivijitnond and Jiro Yasuda
Viruses 2023, 15(10), 2086; https://doi.org/10.3390/v15102086 - 13 Oct 2023
Cited by 2 | Viewed by 1759
Abstract
Herpes B virus (BV) is a zoonotic virus which can be transmitted from macaques to humans, which is often associated with high mortality rates. Because macaques often exhibit asymptomatic infections, individuals who come into contact with these animals face unexpected risks of BV [...] Read more.
Herpes B virus (BV) is a zoonotic virus which can be transmitted from macaques to humans, which is often associated with high mortality rates. Because macaques often exhibit asymptomatic infections, individuals who come into contact with these animals face unexpected risks of BV infections. A serological test is widely performed to investigate BV infections. However, the assay’s sensitivity and specificity appeared to be inadequate, and it does not necessarily indicate ongoing viral shedding. Here, we developed LAMP and qPCR assays aiming to detect BVs with a high sensitivity and specificity in various macaque species and validated them using oral swab samples collected from 97 wild cynomolgus macaques living in Thailand. Our LAMP and qPCR assays detected more than 50 and 10 copies of the target sequences per reaction, respectively. The LAMP assay could detect BV within 25 min, indicating its advantages for the rapid detection of BV. Collectively, our findings indicated that both assays developed in this study exhibit advantages and usefulness for BV surveillance and the diagnosis of BV infections in macaques. Furthermore, for the first time, we determined the partial genome sequences of BVs detected in cynomolgus macaques in Thailand. Phylogenetic analysis revealed the species-specific evolution of BV within macaques. Full article
(This article belongs to the Special Issue Controlling Zoonotic Viral Diseases from One Health Perspective 2025)
Show Figures

Figure 1

Review

Jump to: Research

15 pages, 2004 KiB  
Review
Clinical Strategies and Therapeutics for Human Monkeypox Virus: A Revised Perspective on Recent Outbreaks
by Nilanjan Ghosh, Leena Chacko, Jayalakshmi Vallamkondu, Tanmoy Banerjee, Chandrima Sarkar, Birbal Singh, Rajkumar Singh Kalra, Jasvinder Singh Bhatti, Ramesh Kandimalla and Saikat Dewanjee
Viruses 2023, 15(7), 1533; https://doi.org/10.3390/v15071533 - 12 Jul 2023
Cited by 10 | Viewed by 2773
Abstract
An enveloped double-stranded DNA monkeypox virus (MPXV) is a causative agent of the zoonotic viral disease, human monkeypox (HMPX). MPXV belongs to the genus Orthopoxviridae, a family of notorious smallpox viruses, and so it shares similar clinical pathophysiological features. The recent multicountry HMPX [...] Read more.
An enveloped double-stranded DNA monkeypox virus (MPXV) is a causative agent of the zoonotic viral disease, human monkeypox (HMPX). MPXV belongs to the genus Orthopoxviridae, a family of notorious smallpox viruses, and so it shares similar clinical pathophysiological features. The recent multicountry HMPX outbreak (May 2022 onwards) is recognized as an emerging global public health emergency by the World Health Organization, shunting its endemic status as opined over the past few decades. Re-emergence of HMPX raises concern to reassess the present clinical strategy and therapeutics as its outbreak evolves further. Keeping a check on these developments, here we provide insights into the HMPX epidemiology, pathophysiology, and clinical representation. Weighing on its early prevention, we reviewed the strategies that are being enrolled for HMPX diagnosis. In the line of expanded MPXV prevalence, we further reviewed its clinical management and the diverse employed preventive/therapeutic strategies, including vaccines (JYNNEOS, ACAM2000, VIGIV) and antiviral drugs/inhibitors (Tecovirimat, Cidofovir, Brincidofovir). Taken together, with a revised perspective of HMPX re-emergence, the present report summarizes new knowledge on its prevalence, pathology, and prevention strategies. Full article
(This article belongs to the Special Issue Controlling Zoonotic Viral Diseases from One Health Perspective 2025)
Show Figures

Figure 1

Back to TopTop